Primary Outcomes
The studied patients were followed up for three months after PPCI in terms of re-hospitalization (Figure 1). Re-hospitalization occurred in 10 patients (6.8%) from the case group and 30 patients (25.6%) from the control group, which was statistically significant (P-value: 0.000).
Considering the low mortality rate in STEMI patients who undergo PPCI, in order to investigate the effect of Eptifibatide drug on the consequences and cardiovascular complications, the patients participating in this study in terms of MACE, which includes a combination of death due to cardiovascular diseases, Re-hospitalization, re-infarction, cerebrovascular events, major bleeding, target vessel revascularization (TVR) and target lesion revascularization (TLR) were divided into two groups (Figure 2): The group that experienced MACE and the group that did not experience MACE. The results of our study showed that the occurrence of three-month MACE between the case and control groups did not have a statistically significant difference (42 patients equivalent to 28.6% in the case group versus 41 patients equivalent to 35% in the control group), which means that receiving a maintenance dose of Eptifibatide did not significantly reduce the combination of mortality and morbidity in the patients (P-value: 0.286).
Also, the three-month MACE rate in the case and control groups was compared in different subgroups (Table 3). These findings showed that in our studied patients, the relationship between the occurrence or non-occurrence of MACE after Eptifibatide infusion with hypertension and hyperlipidemia is significant. This means that in patients with hypertension and hyperlipidemia, Eptifibatide infusion has significantly reduced mortality and morbidity. Of course, this relationship was not seen in diabetic patients and smokers.